- 【Updated on May 12, 2025】 Integration of CiNii Dissertations and CiNii Books into CiNii Research
- Trial version of CiNii Research Knowledge Graph Search feature is available on CiNii Labs
- 【Updated on June 30, 2025】Suspension and deletion of data provided by Nikkei BP
- Regarding the recording of “Research Data” and “Evidence Data”
Clinical study of RAK-591 (Etodolac, Hypen<SUP>®</SUP> tablet) in treatment of temporomandibular joint disorders
-
- WAJIMA Kouichi
- Department of Dentistry and Oral Surgery, School of Medicine, Keio University
-
- MURAKAMI Kenichiro
- Department of Oral Maxillofacial Surgery, Graduate School of Medicine, Kyoto University
-
- KAKUDO Kenji
- Second Department of Oral and Maxillofacial Surgery, Osaka Dental University
-
- KOGAI Hideki
- Department of Dentistry and Oral Surgery, School of Medicine, Keio University
-
- TAGAMI Aki
- Department of Dentistry and Oral Surgery, School of Medicine, Keio University Tagami Dental Clinic
-
- FUJIMURA Kazuma
- Department of Oral Maxillofacial Surgery, Graduate School of Medicine, Kyoto University Department of Oral and Maxillofacial Surgery, Kanazawa Medical University
-
- YASUDA Shinya
- Department of Oral Maxillofacial Surgery, Graduate School of Medicine, Kyoto University
-
- TAKAHASHI Katsu
- Department of Oral Maxillofacial Surgery, Graduate School of Medicine, Kyoto University
-
- ARIKA Takumi
- Second Department of Oral and Maxillofacial Surgery, Osaka Dental University
-
- NISHIMURA Kayako
- Second Department of Oral and Maxillofacial Surgery, Osaka Dental University
-
- IMAMURA Yoshiki
- Department of Dental Anesthesiology, Kyushu Dental College
-
- OHURA Kiyoshi
- Department of Pharmacology, Osaka Dental University
Bibliographic Information
- Other Title
-
- 顎関節症に対するRAK‐591(Etodolac:ハイペン錠)の臨床的有効性および安全性に関する検討
Search this article
Description
To evaluate the efficacy and safety of RAK-591 in the treatment of patients with temporomandibular joint disorders, RAK-591 was orally administered, at a dose of 200mg, twice daily, for 4 weeks. In a total of 101 subjects, the efficacy was evaluated in 86 cases, and safety in 90 cases. The improvement rate of pain on exercise (including “improved” or better) was 45.0% (36/80 cases) after 2 weeks, 50.0% (29/58 cases) after 4 weeks, and 57.0% (49/86 cases) at the end of medication (49 improved cases consisted of 16 completely improved cases at 2 weeks, and 33 improved-or-better-rated cases at 4 weeks). The pain on exercise on VAS was 51.8mm on average before administration, and 16.1mm on average at the end, showing a significant reduction (p<0.001). The maximal range of passive and pain-free opening expanded from 32.9mm, on average, before administration, to 41.4mm, on average, after 2 weeks, and 42.6mm, on average, at the end, indicating significant improvement (p<0.001). On the other hand, adverse reactions were observed in 17 of 90 cases (18.9%), but none were serious. The main adverse reactions were gastrointestinal symptoms, and these recovered after stopping the medication without any treatment.<BR>In conclusion, RAK-591 exhibited good clinical efficacy and high safety in the treatment of temporomandibular joint disorders, and it was considered to be a useful drug.
Journal
-
- Journal of Temporomandibular Joint
-
Journal of Temporomandibular Joint 13 (2), 248-257, 2001
The Japanese Society for Temporomandibular Joint
- Tweet
Details 詳細情報について
-
- CRID
- 1390282679396477184
-
- NII Article ID
- 10008983709
-
- NII Book ID
- AN10093617
-
- ISSN
- 18844308
- 09153004
-
- Text Lang
- ja
-
- Data Source
-
- JaLC
- CiNii Articles
-
- Abstract License Flag
- Disallowed